H1 2020 Financial Information

 

• Cash and cash equivalents at €52.2m as at June 30, 2020
  
  

Daix (France), July 6, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of June 30, 2020.

As of June 30, 2020, Inventiva’s cash and cash equivalents stood at €52.2 million compared to €46.9 million as of March 31, 2020 and €35.8 million as of December 31, 2019.

Inventiva’s net cash flow amounted to €16.4 million in the six months ended June 30, 2020 compared to (€19.6) million in the first half of 2019. Net cash used in operating activities was (€10.7) million and (€18.7) million in the first half of 2020 and 2019, respectively. Net cash provided by (used in) financing activities was €28.1 million and (€0.1) million in the first half of 2020 and 2019, respectively. 

The Company believes that its cash and cash equivalents as of June 30, 2020 will be sufficient to fund its operating activities into the third quarter of 2021.

                                                                                                 ***